

IN THE CLAIMS:

37. (Previously presented) A polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1, wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

- (a) amino acids 6-11 OF SEQ ID NO: 1, and
- (b) amino acids 11-20 of SEQ ID NO: 1.

38. (Previously presented) The polypeptide according to claim 37, further comprising a cysteine residue at the carboxyl terminus and the amino terminus of the polypeptide, thereby providing a capability to form a cyclic polypeptide via formation of a disulfide bond.

39. (Previously presented) The polypeptide according to claim 37, further comprising an additional amino acid residue located at least one position selected from the group consisting of the carboxyl terminus and the amino terminus of the polypeptide, wherein the additional amino acid residue is selected from the group consisting of cysteine, lysine, glutamic acid, arginine, asparagine, glutamine, tryptophan, serine, threonine and aspartic acid.

40. (Previously presented) The polypeptide according to claim 39, wherein the additional amino acid residue is derivatized or derivatizable.

41. (Previously presented) The polypeptide according to claim 40, wherein the terminal amino acid residue is cysteine derivatized with S-(2-pyridyl) dithio.

43. (Previously presented) A multimeric polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1, wherein the polypeptide comprises at least two polypeptide constituents that comprise a 6 to 23

amino acid portion of SEQ ID NO: 1, and wherein the polypeptide constituents have at least one amino acid sequence selected from the group consisting of:

- (a) amino acids 6-11 OF SEQ ID NO: 1, and
- (b) amino acids 11-20 of SEQ ID NO: 1, wherein the polypeptide constituents do not comprise a mature short consensus repeat-3 and the polypeptide constituents are covalently linked to a core structure selected from the group consisting of a lysine derivative, tris (aminoethyl) amine and 1,2,4,5 benzene tetracarboxylic acid.

44. (Previously presented) The multimeric polypeptide according to claim 43, wherein the core structure comprises a multiple antigen peptide (MAP).

46. (Previously presented) The multimeric polypeptide according to claim 43, wherein the multimeric polypeptide comprises at least two and no more than eight polypeptide constituents.

47. (Previously presented) The multimeric polypeptide according to claim 43, wherein the MAP peptide comprises (Lys)₄ (Lys)₂ Ala-OH).

48. (Previously presented) A chimeric polypeptide comprising a host protein and as an insert a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1, wherein the polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 has at least one amino acid sequence selected from the group consisting of:

- (a) amino acids 6-11 of SEQ ID NO: 1, and
 - (b) amino acids 11-20 of SEQ ID NO: 1,
- wherein the polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 is inserted into the host protein.

49. (Previously presented) The chimeric polypeptide according to claim 48, wherein the host protein contains at least one short consensus repeat of complement receptor 1.

50. (Previously presented) The chimeric polypeptide according to claim 48, wherein the host protein is a plasma protein.

51. (Previously presented) The polypeptide according to claim 37, wherein the polypeptide is selected from the group consisting of:

linear CNPGSGGRKVFELVGEPsiYC (SEQ ID NO: 4);

cyclic CNPGSGGRKVFELVGEPsiYC (SEQ ID NO: 4);

SGGRKVFELVGEPsiYC (SEQ ID NO: 5);

CGGRKVFC (SEQ ID NO: 7); and

FELVGEPsiYSTSNDQVGIWSG (SEQ ID NO: 8).

52. (Previously presented) A process for preparing a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1, wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, comprising the steps of: condensing peptide units, in solid phase synthesis to form the polypeptide, and recovering the polypeptide.

53. (Previously presented) A process for preparing a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 , wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

- (a) amino acids 6-11 of SEQ ID NO: 1, and
- (b) amino acids 11-20 of SEQ ID NO: 1, comprising the step of: expressing DNA encoding the polypeptide in a recombinant host cell, and recovering the polypeptide.

54. (Previously presented) An isolated polynucleotide encoding a polypeptide having only a partial sequence from short consensus repeat 3 of complement receptor 1 , wherein the polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

- (a) amino acids 6-11 of SEQ ID NO: 1, and
- (b) amino acids 11-20 of SEQ ID NO: 1.

55. (Previously presented) The polynucleotide according to claim 54, wherein the polynucleotide is in an expression vector.

56. (Currently amended) The polynucleotide according to claim 54, wherein the polynucleotide is in an expression vector and the expression vector is in a host cell, by transformation or transfection.